Aslan Pharmaceuticals Return On Equity vs. Price To Book

ASLNDelisted Stock  USD 0.60  0.03  4.76%   
Based on Aslan Pharmaceuticals' profitability indicators, Aslan Pharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Aslan Pharmaceuticals' ability to earn profits and add value for shareholders.
For Aslan Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aslan Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aslan Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aslan Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aslan Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aslan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Aslan Pharmaceuticals Price To Book vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Aslan Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Aslan Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Aslan Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in price to book category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aslan Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Aslan Price To Book vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Aslan Pharmaceuticals

Return On Equity

 = 

Net Income

Total Equity

 = 
-4.27
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Aslan Pharmaceuticals

P/B

 = 

MV Per Share

BV Per Share

 = 
2.14 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Aslan Price To Book Comparison

Aslan Pharmaceuticals is currently under evaluation in price to book category among its peers.

Aslan Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Aslan Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aslan Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Aslan Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Aslan Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company was founded in 2010 and is headquartered in Singapore. Aslan Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 27 people.

Aslan Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Aslan Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aslan Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aslan Pharmaceuticals' important profitability drivers and their relationship over time.

Use Aslan Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Aslan Pharmaceuticals Pair Trading

Aslan Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Aslan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aslan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aslan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aslan Pharmaceuticals to buy it.
The correlation of Aslan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Aslan Pharmaceuticals position

In addition to having Aslan Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Manufacturing Thematic Idea Now

Manufacturing
Manufacturing Theme
Companies that provide goods across residential, commercial and industrial construction such as machinery, tools, or lumber production. The Manufacturing theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Manufacturing Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Other Consideration for investing in Aslan Stock

If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Fundamental Analysis
View fundamental data based on most recent published financial statements